• 1
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 7606
  • 2
    Chapple CR. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Invest Drugs 2004; 13: 1493500
  • 3
    Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype selective muscarinic receptor antagonists. Eur J Pharmacol 1998; 394: 28592
  • 4
    Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000; 129: 4169
  • 5
    Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005; 144: 108999
  • 6
    Tyagi S, Tyagi P, Van-Le S, Yoshimura N, Chancellor MB, De Miguel F. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 2006; 176: 16738
  • 7
    Moore KH, Gilpin SA, Dixon JS, Richmond DH, Sutherst JR. Increase in presumptive sensory nerves of the urinary bladder in idiopathic detrusor overactivity. Br J Urol 1992; 70: 3702
  • 8
    Yoshida M, Inadome A, Maeda Y et al. Non-neuronal cholinergic system in human bladder urothelium. Urology 2006; 67: 42530
  • 9
    Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autocoid Pharmacol 2002; 22: 13345
  • 10
    Guerrero K, Emery S, Owen L, Rowlands M. Intravesical oxybutynin: practicalities of clinical use. J Obstet Gynaecol 2006; 26: 1413
  • 11
    Chaiyaprasithi B, Mang CF, Kilbinger H, Hohenfellner M. Inhibition of human detrusor contraction by a urothelium derived factor. J Urol 2003; 170: 1897900
  • 12
    Scott R, Chapple C, Chess-Williams R. Which muscarinic receptor subtype causes the release of the urothelium derived inhibitory factor in the female pig bladder. Eur Urol Suppl 2005; 4: 55 Abstract
  • 13
    Mukerji G, Yiangou Y, Grogono J et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006; 176: 36773
  • 14
    Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001; 21: 2438
  • 15
    Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002; 136: 6413
  • 16
    Hinata N, Shirakawa T, Okada H, Achaya B, Kamidono S, Gotoh A. Quantitative analysis of the levels of expression of muscarinic receptor subtype RNA in the detrusor muscle of patients with overactive bladder. Mol Diagn 2004; 8: 1722
  • 17
    Bayliss M, Wu C, Newgreen D, Mundy AR, Fry CH. A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle from stable, unstable and obstructed bladders. J Urol 1999; 162: 18339
  • 18
    Moore KH, Lam DS, Lynch W, Burcher E. The tachykinin NK-2 receptor antagonist SR48968 does not block noncholinergic contractions in unstable human bladder. Peptides 2002; 23: 115560
  • 19
    Sellers DJ, Chapple CR, Hay DP, Chess-Williams R. Depressed contractile responses to neurokinin A in idiopathic but not neurogenic overactive human detrusor muscle. Eur Urol 2006; 49: 5108
  • 20
    Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder. J Urol 2003; 169: 8438
  • 21
    Booth CM, Whiteside CG, Turner-Warwick RT. A long-term study of the persistence of the urodynamic characteristics of the unstable bladder. Br J Urol 1981; 53: 3104
  • 22
    Morris AR, Westbrook JI, Moore KH. Idiopathic detrusor overactivity in women – A 5–10 year longitudinal study of outcomes. Neurourol Urodyn 2003; 22: 4602
  • 23
    Schurch B, De Sèze M, Denys P et al. Botulinum toxin A (Botox®) in neurogenic urinary incontinence: results from a multi centre randomized, controlled trial. Neurourol Urodyn 2004; 23: 60910
  • 24
    Fowler CJ. Intravesical treatment of overactive bladder. Urology 2000; 55 (Suppl.): 604